Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants

Drug-Induced Phototoxicity: A Systematic Review

(2018) Whan B. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Encorafenib and Binimetinib: First Global Approvals

(2018) Matt Shirley   DRUGS

Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damage

(2018) Susanne Kimeswenger et al.   MELANOMA RESEARCH

Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma

(2017) Adil Daud et al.   ONCOLOGIST

Process of Fragment-Based Lead Discovery—A Perspective from NMR

(2016) Rongsheng Ma et al.   MOLECULES

Combination therapy of melanoma using kinase inhibitors

(2015) Markus V. Heppt et al.   CURRENT OPINION IN ONCOLOGY

The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing

(2015) J.A. Woods et al.   JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY

Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease

(2014) C. Brugière et al.   BRITISH JOURNAL OF DERMATOLOGY

Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.

(2014) L. Vanneste et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Vemurafenib: an unusual UVA-induced photosensitivity

(2013) Pauline Gelot et al.   EXPERIMENTAL DERMATOLOGY

Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities

(2012) R. Sinha et al.   BRITISH JOURNAL OF DERMATOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Cutaneous toxicities of RAF inhibitors

(2012) Rachael Anforth et al.   LANCET ONCOLOGY

Vemurafenib: the first drug approved for BRAF-mutant cancer

(2012) Gideon Bollag et al.   NATURE REVIEWS DRUG DISCOVERY

Ultraviolet A and Photosensitivity during Vemurafenib Therapy

(2012) Reinhard Dummer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors

(2010) Alfonso Zambon et al.   JOURNAL OF MEDICINAL CHEMISTRY

Array of cutaneous adverse effects associated with sorafenib

(2009) Heidi H. Kong et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Reactive oxygen species assay-based risk assessment of drug-induced phototoxicity: Classification criteria and application to drug candidates

(2008) Satomi Onoue et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

(2008) Caroline Robert et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Glutathione: Overview of its protective roles, measurement, and biosynthesis

(2008) Henry Jay Forman et al.   MOLECULAR ASPECTS OF MEDICINE

High-throughput reactive oxygen species (ROS) assay: An enabling technology for screening the phototoxic potential of pharmaceutical substances

(2007) Satomi Onoue et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS